Literature DB >> 11466348

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

J L Cannons1, P Lau, B Ghumman, M A DeBenedette, H Yagita, K Okumura, T H Watts.   

Abstract

A costimulatory member of the TNFR family, 4-1BB, is expressed on activated T cells. Although some reports have suggested that 4-1BB is primarily involved in CD8 T cell activation, in this report we demonstrate that both CD4 and CD8 T cells respond to 4-1BB ligand (4-1BBL) with similar efficacy. CD4 and CD8 TCR transgenic T cells up-regulate 4-1BB, OX40, and CD27 and respond to 4-1BBL-mediated costimulation during a primary response to peptide Ag. 4-1BBL enhanced proliferation, cytokine production, and CTL effector function of TCR transgenic T cells. To compare CD4 vs CD8 responses to 4-1BBL under similar conditions of antigenic stimulation, we performed MLRs with purified CD4 or CD8 responders from CD28(+/+) and CD28(-/-) mice. We found that CD8 T cells produced IL-2 and IFN-gamma in a 4-1BBL-dependent manner, whereas under the same conditions the CD4 T cells produced IL-2 and IL-4. 4-1BBL promoted survival of CD4 and CD8 T cells, particularly at late stages of the MLR. CD4 and CD8 T cells both responded to anti-CD3 plus s4-1BBL with a similar cytokine profile as observed in the MLR. CD4 and CD8 T cells exhibited enhanced proliferation and earlier cell division when stimulated with anti-CD3 plus anti-CD28 compared with anti-CD3 plus 4-1BBL, and both subsets responded comparably to anti-CD3 plus 4-1BBL. These data support the idea that CD28 plays a primary role in initial T cell expansion, whereas 4-1BB/4-1BBL sustains both CD4 and CD8 T cell responses, as well as enhances cell division and T cell effector function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466348     DOI: 10.4049/jimmunol.167.3.1313

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

1.  Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.

Authors:  Lara Myers; Chikara Takahashi; Robert S Mittler; Robert J Rossi; Anthony T Vella
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-14       Impact factor: 11.205

2.  Microarray analysis of Aeromonas hydrophila cytotoxic enterotoxin-treated murine primary macrophages.

Authors:  C L Galindo; A A Fadl; J Sha; A K Chopra
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

3.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

4.  Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model.

Authors:  Elizabeth W Newcomb; Yevgeniy Lukyanov; Noriko Kawashima; Michelle Alonso-Basanta; Shu-Chi Wang; Mengling Liu; Maria Jure-Kunkel; David Zagzag; Sandra Demaria; Silvia C Formenti
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

5.  4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Authors:  Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard L Kaufman
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

6.  Molecular mechanisms of induction of antigen-specific allograft tolerance by intranasal peptide administration.

Authors:  Katy Derbyshire; Caroline Addey; David Coe; Daniel W Stuckey; Hasan Muezzin; Jason A Bubier; Daniel J Shaffer; Derry C Roopenian; Jian-Guo Chai; Diane M Scott
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

7.  4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.

Authors:  Hua Zhang; Kristen M Snyder; Megan M Suhoski; Marcela V Maus; Veena Kapoor; Carl H June; Crystal L Mackall
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

8.  T cell costimulatory molecules in anti-viral immunity: Potential role in immunotherapeutic vaccines.

Authors:  Tania H Watts; Edward M Bertram; Jacob Bukczynski; Tao Wen
Journal:  Can J Infect Dis       Date:  2003-07

9.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

10.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.